ABCDEFGHIJKLMNOPQRSTUVWXY
1
Requesting Institution/ OrganisationApplicant Name Purpose Material RequestedFundingDecision Request DateDecision DatePublication DOIOther outcomes
2
University of OxfordTheresa Lambe & Sarah GilbertVaccine DevelopmentSera - 5mlInternal fundingApproved29.02.202024.03.2020
3
AstraZenecaMark EsserIdentify B cells that secrete neutralizing antibodies against the SARS-CoV-2 virus.Convalescent serum – 5mlInternal fundingApproved17.03.202024.03.2020
4
Biogene ResearchNelson NazarethTesting against CDC/PHE primer/probe set40 swabsNo fundingReapply when funded11.03.202024.03.2020
5
Liverpool School of Tropical MedicineEmily AdamsAssay DevelopmentSerum from 10 convalescent patients 5mlDFID/WellcomeApproved10.03.202024.03.2020https://doi.org/10.12688/wellcomeopenres.16522.1
6
University of EdinburghFrancisca MutapiDevelop an elisa-based immunoassay for detecting Covid-19 antibodies100ul convalescent plasma/serumApproved16.03.202024.03.2020
7
PEPperPRINTVolker StadlerDiagnostic COVID-19 peptides in collaboration with University of EdinburghConvalescent serum -1mlPEPperPrint: internal funding UoE: NIHRDeclined16.03.202024.03.2020
8
RegeneronSumathi SivapalasingamProduction of therapeutic antibodies from B cells50ml of whole bloodInternal fundingApproved10.03.202024.03.2020
9
University College LondonJoseph JacobLink clinical parameters and imaging features in A&E with likelihood for ITU or requiring ventilationClinical and blood results dataWellcome and NIHR BRC fundingApproved24.03.202013.04.2020
10
University of LiverpoolCarlo PalmieriPresentation, management and outcome of patients with COVID-19 and cancerClinical dataInternal fundingApproved01.04.202013.04.2020S934-S973. 10.1016/annonc/annonc289. Established CCP Cancer-UK.
11
University of OxfordRoman FischerDetermine the plasma proteome in COVID-19 patientsPlasma - 50µl from 400 patientsInternal fundingApproved, recommended that this is done collaboratively with funded ISARIC-4C partners.02.04.202013.04.2020
12
Imperial College LondonKatrina PollockUnderstanding the pathogenesis through standard lab techniques like ELISAsSerum and Plasma. 1ml vial of urine and oral swabs if available. Male patients moderate and severeMRC/UKRI rolling funding callApproved, pending d/w PO to preserve samples03.04.202013.04.2020
13
Health Protection Scotland University of GlasgowElisabeth Dickson Antonio HoValidate a serological ELISA assay for immunological response curveSerum samples at least 500ul. Helpful if it's pared as acute and convalescent. N=50.Governmentally fundedApproved28.03.202013.04.2020
14
Quotient BDReginald ClaytonDiagnostic serology assay for use in hospitals and blood testing insitutions.5ml plasma or serum samples. Preferably dozensQuotient R&D budget.Approve for diagnostic evaluation platform.28.03.202013.04.2020
15
University of EdinburghChris HaleyGWAS of DNA methylationAccess to DNA samplesFunding pendingApprove if funded06.04.202013.04.2020
16
University of EdinburghAlex von KriegsheimQuantify lipids and metabolites using mass spectrometry lipidomicsPlasma - 100µl from 600 patientsFunding pendingApproved06.04.202013.04.2020
17
University of LiverpoolSimon AbramsValidate the multivariable prognostic model established in Chinese cohorts. Compare prognostic variable with circulating histones.Plasma - 500µl from 200 patientsInternal fundingApproved06.04.202013.04.2020
18
Brighton and Sussex Medical SchoolFlorian KernExpansive peptide array to detect antibody responses spanning full proteome10-20ul serum. Recovered patients. Clinical course must be known. ~ 100 samples.Not yet fundedApproved if funded22.03.202013.04.2020
19
University of LiverpoolJames StewartDevelopment and selection of antigens for diagnostics and vaccine candidates. Establish ELISAs using antigen proteins2ml convalescent serum. 6+ patients.Core BBSRC funds. University of Kent funds.Approved for diagnostic evaluation platform.07.04.202013.04.2020
20
University of LiverpoolQingging ZhangSuper-neutralising antibodies pull-down using Spike protein conjugated beadsSerum – 10ml from 20 patientsNHS R&D grantApproved08.04.202013.04.2020
21
University of GlasgowJohn McLauchlanHost genotyping for IFNL4 for COVID-19 patients.1-2ml serum of up to 400 patients.Core funded.Duplication of planned analyses, will share data when available.08.04.202013.04.2020
22
GSKJagtar NijjarIdentify disease endotypes and develop predictive algorithms for stratifying patients with poor outcomesDemographic outcomes, clinical data and cytokine dataInternal fundingApproved 06.04.202013.04.2020
23
University of EdinburghDamian MoleStratification of COVID-19 patients using 2 established metabolic pathway panels.100ul plasma or serum of 500 patientsMRC fellowship and existing industry collaborationsApproved13.04.202028.04.2020
24
British HIV Association GroupSophie KellyInvestigate infection rate and disease course of COVID-19 in HIV patients.Periodic reports of HIV positive patients. Access to immunology, serology and PCR results. Every 1-3 months. Samples: Serum/plasma 500ul from as many HIV-positive patients as possible.Internally fundedApproved13.04.202028.04.202010.1093/cid/ciaa1605.
25
Imperial College LondonRoya E Haghihat-KhahRNA seq to investigate differential gene expression between patient groups (eg age, sex, hypertension treatment and recovery)RNA from Oracol or viral throat swabs. RNA or materials from 300 patietns.UKRI funding in processApproved if funded14.04.202028.04.2020
26
University College LondonBenny ChainMachine learning to identify T-cell receptor signature that predicts clinical outcomes.Blood RNA (600ng extracted from tempus tubes) Day 1,3,9 and 28. 300 longitudinal patients.UKRI funding application depending on sample accessApproved14.04.202028.04.2020
27
University of EdinburghYanick CrowMeasuring INF-alpha in COVID-19 patients using an ultrasensitive digital ELISA assaySerum or plasma (100ul)Funding in place for 100 samples. Funding pending for 1000+ samples.Approved 24.04.202028.04.2020https://doi.org/10.1101/2020.10.08.20209411
28
University of EdinburghPaul BrennanInfrared spectroscopy-based test for COVID-19 risk stratification and immunity50ul serum from day 1, 9 and 28 of 200 patients. If not possible, Day 1 and 28 possible.UKRI, CSO and others for validation phase. Algorithm training can start without funding.Suitable serum samples don't exist. Decline.21.04.202028.04.2020
29
Monash University AustraliaRoss PearsonRisk prediction to support clinical decision making and triaging of patients to hospital or community-based care.50 cases of clinical data - ISARIC data formsFunding in place, NSW and QLD health and Digital Health CRCForms part of planned investigations in original application. Recommend collaborative analysis21.04.202028.04.2020
30
University of OxfordSusie DunachiePhenotypic and functional T-cell responses to COVID-19 vaccine targets and identify metabolism differences in Type 2 diabetes patients.4 million PBMCs from 50 COVID-19 patients with and without Type 2 diabetes at Day 1 and Day 28 (where available). Linked patient metadata including age, gender, disease severity, supportive care received, trial treatments and outcome. Matched for age, gender and disease severity at Day 1.Salary and lab running costs covered by existing grants. Applying for Diabetes UK COVID-19 Rapid Response for further funding.Approved20.04.202028.04.2020PITCH Study protocol
31
University of Liverpool and Liverppol University Hospitals NHS Foundation TrustDouglas B Kell (PI) Andrew S DavisonUntargeted metabolomics of serum samples during COVID-19. Longitudinal sampling to asses relationships between metabolites and infection, disease progression, severity and outcome. Samples will be analysed using high-resolution mass spectrometry.Surplus serum and anonymised metadata (age, sex, disease status and other clinical information) collected in Liverpool Clinical Laboratories. Each sample requires a minimum volume of 150ul.Funding pendingApproved21.04.202028.04.2020
32
Imperial College LondonAubrey CunningtonDevelopment of a mathematical model of viral load dynamics using host response data to predict outcome of disease and allow better treatment stratification.Data - serial viral load measurements (Ct values etc). Clinical data and demographic data. Whole blood RNA seq data and blood immune response data. Upper airway mucosal response data with paired viral load data. Common genetic polymorphisms.Do not require funding to intitiate work. Will apply for rapid response calls for staff time.Approved22.04.202028.04.2020
33
University of LiverpoolJonathan CattrallInvestigating neurological disease in COVID-19 through clinical features, risk factors and analysis of CSF and sera to understand disease mechanisms.Data - analysis of patient data with features suggestive of neurological disease. Determine risk factors for neurological disease. If protocols and ethics allow, detailed questionnaire to be sent to research sites and contact patients for more info re outcome. Samples- CSF (2ml - min of 100ul doable) and serum (2ml). Unsure how many samples may be available.Funding from NIHR HPRU in EZIApproved24.04.202028.04.2020
34
University of LiverpoolAlicia Waite Ingeborg WeltersAnalysis of endothelial and clotting biomarkers by correlating biochemical findings with imaging results (CXR, CT, US) to determine if COVID-19 cause a prothrombotic state. Serum, EDTA plasma (and citrate plasma). 200ul for each Internally funded and applying for UKRIApproved27.04.202030.04.2020
35
ONSJonny TinsleyEstimate the relationship between in-hospital outcomes of patients admitted with COVID-19 and their demographic, socioeconomic and clinical risk factor profiles. Patients demographics, admission details, treatment, comorbidities, outcomes for patients spanning England, Scotland and Wales. Internally fundedApproved28.04.202030.04.2020
36
University College LondonJamie BrownLive rapid review on smoking and COVID-19Endpoint variables, socio-demographic and general health variables and variables relating to smoking status, smoking cessation history, use of stop smoking medications or alternative sources of nicotine.Cancer Research UKApproved29.04.202030.04.2020
37
McGill Quebec, CanadaBrent RichardsElucidate host genetic determinants and develop predictive models for COVID-19 severity by using phenotypic data. All phenotypic data (biochemical, hematological, immunological data), host genotype data, RNA seq data (D1,3,9 and 28). Viral sequencing data for host genetics and viral sequence. Quebec provincial government and Fonds de recherche du Quebec - Sante.Approve for collaboration - similar to WP529.04.202030.04.2020
38
University of LeicesterKamlesh KhuntiIdentify vulnerable groups at risk of disease. DHSC letter of support.Clinical data collected on admission, daily and outcome forms. Differences in outcomes based on ethnicity, co-morbidities, obesity and socio-economic status. NIHR ARC East MidlandsApproved30.04.202030.04.2020
39
University of EdinburghGwo-Tzer HoInvestigate DAMPs assays as prognostic marker. Drug treatments that block the action of DAMPs. Clarify role of gut ACE2 expression and transmissibility. Understanding gut microbiome and whether clinial outcome can be predicted from GI microbiome data.Serum and plasma (5mls) - 200 patients (100 ICU vs 100 non-ICU). Stools (5-10ml) 1000 patients with associated clinical data (cluster 3 - with GI symptoms vs non-GI symptoms). Clinical data - 1000 patients stratified by disease severity and clinical phenotype - with or without diarrhea. Helmsley Trust, ERC, Scot Government RESAS, BBSCRC, and funds form Scottish Senior Fellowship.Approved for stool samples01.05.202002.06.2020
40
Tribal GroupAlan SwanData analytics for risk factors Data behind BMJ articleInternally fundedApproved29.04.202002.06.2020
41
Imperial College LondonZoltan Takats James Kinross Lauren Ford *In combination with Request 47 DumasAmbient mass spectrometry techniques for metabolite biomarkers of COVID-19 status and host immune response and a protease assay for a rapid, point-of-care test. Combined nose and throat swabs, otherwise a throat swab or nasopharyngeal swab alone. As many as possible. Imperial Biomedical Research Centre.Approved for stool samples04.05.202002.06.2020
42
University Hospitals Coventry & WarwickshireJames SeanCharacterise disease and predict oucomes by combining ISARIC-4C data with samples collected at UHCW with AI and digital pathologyAll patient data collected for the ISARIC-4C trial CRF under UHCW, George Elliot Hospital NHS Trust and South Warwickshire NHS Foundation Trust. Wellcome funding, UHCW NHS trust and additional applications to MRC Rapid Response Rolling call.Approved01.05.202002.06.2020
43
University of LiverpoolLance Turtle Julian HiscoxDetermining the ability of culturing SARS-CoV-2 virus using respiratory tract swabs.20-50 respiratory tract swabs from patients with severe COVID-19 and mild/moderate disease respectively. Internally fundedApproved01.05.202002.06.2020
44
University of SouthamptonDavid CoggonImprove occupational risk assesments - estimates of risk by sex, age and comorbidities with sufficient numbers.Data file abstracted from BMJ article - limited to patients between 20-74 years.Internally fundedApproved04.05.202002.06.2020
45
Imperial College LondonMarc-Emmanuel Dumas Julian Griffin Zoltan Takats Peter Openshaw *In combination with Request 43 TakatsMetabolomic profiling of COVID-19 to improve mechanistic understanding, provide insights into secondary biological effects and further develop prognostic markers.All 650 patients at 4 timepoints - 2600 samples. Plasma (or serum) 375ul per sample. Urine 275ul per sample. Stool 500mg per sample. Swab metabolomics - Prof Takats application (Request 43)Imperial Biomedical Research Centre.Approved04.04.202002.06.2020
46
University of Liverpool University of Sheffield University of OxfordLance Turtle Paul Klenerman Thusan DeSilva Susie Dunachie Ellie Barnes Alex Mentzer Phenotypic and functional T-cell response to SARS-CoV-2 including vaccine targets. Greater capacity and samples than original ISARIC-4C aims of characterising the immune response.30-40 million PBMCs from all donors sampled. Final sample sizes to be determined as part of the ISARIC-4C follow up WP9. Internally funded by University of Liverpool and University of Oxford. Approved04.05.202002.06.2020PITCH Study protocol
47
University of OxfordAndrew SoltanAI algorithms to rapidly identify COVID-19 illness at the front-door of hospitals.Essential data: Admission blood tests - FBC, U&Es, LFTs, CRP, Clotting function, Microbiology, SARS-CoV-2 results, influenza results (where tested) admission observations (if available). Desirable: Single set of pre-morbid blood tests values for the same parameters. ESPRC Approved05.05.202002.06.2020
48
Imperial College LondonRoberta Forlano Mark Thurz Pinelopi Manousou Benjamin MullishRisk factors of COVID-19 patients with non-alcoholic fatty liver diseaseClinical data - demographics, blood test results, details regarding presentation, admission and clinical outcomes.Imperial Biomedical Research Centre.Approved05.05.202002.06.2020
49
Personal CapacityEduardo HenriqueHighlighting severity of COVID-19 to better inform Brazilian populationClinical data - demographics, details regarding presentation, admission and clinical outcomes.Self-fundedDeclined - no institutional support03.05.202002.06.2020
50
MathworksPeter MaloneyDevelopment of a multifactorial RSM tool to improve outcomes and triaging of patientsRaw data used to create survival from onset plot and Symptoms on presentation to hospital bar graph. Internally fundedRetracted05.05.202002.06.2020
51
London School of Hygiene and Tropical MedicineKatherine Atkins Stephane HuePhylogenetic modeling to evaluate the role of hospital-acquired infection in sustaining UK transmissionRequest for CO-CIN data. For all patients with positive SARS-CoV-2 test and viral sequence from nasal/saliva swab sample. Data variables - employed as healthcare worker, DOB/age, outer postcode, onset data, admission date, readmission?, transfer from other facility? collection date for samples, outcome and date, full lenght viral genome seq for SARS-CoV-2Internally fundedApproved06.05.202002.06.2020
52
University of NottinghamA Abishek Georgina Nakafero Tim Card Matthew Grainge Determining effect of immune-surpressing medicines on COVID-19 outcomeClinical data - outcomes, risk factors - immune-suppressive medication used at time of hospital admission, covariates and other data fields such as vital signs at admission, date of onset, COVID-19 detected by PCR.University of Nottingham and Nottingham NIHR-BRCDuplication of planned analyses 06.05.202012.07.2020
53
ExplantlabDavid LangtonInvestigating variations in the major histocompatibility complex and COVID-195-10ml EDTA - intubated/CPAP, <65yrs, no comorbidities. Total of 75 patients. Would require accompanying demographic dataInternally fundedResubmission07.05.202012.07.2020
54
Liverpool University Hospitals Foundation NHS trust and University of LiverpoolSree SubramianLink between Vit D deficiency and at risk groups for severe COVID-19 illness and death.Plasma or serum (500ul). All patients fom Tier 1, or 500 approx. would require 0.5ml plasma or serum (they have 250 tier 0 patients of their own)£20 000 funding in place for Vit D assays.Approved for Tier 007.05.202002.06.2020
55
Liverpool School of Tropical MedicineRyan Robinson Andrea Collins Investigate reationship between immunosuppressive treatments and mortality risk of COVID-19 patients.Immunosuppressive therapy duration and type, demographics, requirement for HDU/ITU admission, mortality rate and duration of inpatient stay.Internally fundedApproved07.05.202002.06.2020
56
University College LondonNikhil SharmaInvestigating differences in the gut microbiome and clinical course of COVID-19Stool samples (<0.5g) - 1000 (different subsets) and clinical metadataFunding pendingApproved12.05.202002.06.2020
57
Trisomy 21 Research SocietyAndre Strydom Stephanie Sherman Mara DierssenImpact of COVID-19 on individuals with Down Syndrome.Clinical data incl demographics, co-morbidities, medication,treatment, outcomes etc.LuMind IDSC Foundation and other Down Syndrome organisationsApproved11.05.202002.06.202010.1101/2020.11.03.20225359.
58
Your.mdJonathan Carr-BrownCompare percentages from ISARIC-4C BMJ paper to global symptom mapperList of symptoms not noted in paperSelf-fundedApproved11.05.202002.06.2020
59
Queen's University BelfastChristina BrancoInflammatory signals that can affect microvascular function such as endothelial activation, permeability or intercellular recruitment signals.Plasma (500ul min); clotted serum (100ul min); blood in blood RNA tube (200ul min). At least 20 depending on variation between disease severity. Access to samples required to secure funding.Denied, duplication of planned work15.05.202002.06.2020
60
University of MiamiManish KuchakullaAI tool to generate a neural network to improve diagnosis and predicting prognosis of disease.Clincal data: demographics, symptoms, lab values and co-morbidities.Part internally funded, part funded by philanthropy.Approved15.05.202002.06.2020
61
University of SheffieldFelipe SoaresAn intelligent system for the pre-triage of COVID-19 suspected patients based on simple blood exams and data science to benefit resource-poor settings in LMICs.Clinical data: Demographics, onset and admission, vital signs at admission, co-morbidities, daily lab results, daily treatment, pathogen testing, treatment, outcome.Funding pendingApproved - part of consortium15.05.202002.06.2020
62
Loughborough UniversityLiam HeaneyThe impact of the gut microbiome for the risk/severity of COVID-19, by investigating gut microbiota-derived metabolites using mass spectrometry-based assays.Serum (250ul) maximum number available at visit 1. Clinical data - demographics, laboratory results, and outcome data.Funding application dependent on sample approval.Approved for discussion14.05.202002.06.2020
63
University of OxfordEmily ThorntonGut inflammation and the microbiome and adverse patient outcomesStool samples (>500mg) as early in disease matched with immunophenotyping data from ISARIC, clinical phenotype and routine lab data. Internal funding, will apply for external funding with pilot data.Approved for discussion18.05.2020
64
University of EdinburghAndrea WilsonData-driven now-casting & fore-casting of health-care resource requirements associated with COVID-19 in Edinburgh and South-East ScotlandCO-CIN data from Tiers 0. 1, 2 from Scotland and rest of UK.Internally fundedApproved 18.05.202002.06.2020
65
CRN Yorkshire and HumberRebecca ByrneBAME outcomes and participation in research in Yorkshire and HumberAccess to CRF data - ethnicity and outcome measures. 26.06.2020 - Access to Tier 0 for BAME breakdown Internally fundedApproved27.05.202012.07.2020
66
Royal Wolverhampton NHS TrustSrinivisan VenkatachalamCOVID Hyperinflammation study. Use of ISARIC-4C dataset for the Wolverhampton patients to support COVIDHI study.Clinical characteristics of all COVID patients entered into ISARIC from The Royal Wolverhampton NHS TrustInternally fundedApproved19.05.202012.07.2020
67
Imperial College LondonRoy Anderson Chris HadjichrysanthouUnderstanding temporal patterns of viral dynamics and associated immune response activated to clear the virus. Mathematical models to investigate immunological mechanisms involved in controlling viral growth and impact of preventative and therapeutic interventions.Quantitative SARS-CoV-2 RNA data over time (multiple time points). Sample demographics, system onset, admission signs and symptoms, co-morbidities, vital signs at admission, temperature. Any medication or treatment administered. ICU admission. Host immune responses measured over time - immune mediators, cellular, humoral.MRC and LCNTDR. Applications for UKRIDuplication of planned work, will share data when available26.05.202012.07.2020
68
BG ResearchNelson NazarethResubmission as per feedback - Direct RT-qPCR amplification and detection of SARS-CoV-2 from nasal swab eluates, saliva, etc. Working in Emily Adams in LSTM lab.40 positive combined nose and throat swabs or alone. Preferably from same individual from day 1,3,9 as per protocol or 40 from day 1.DASA accelerator COVID research programPending sample availability19.05.202012.07.2020
69
Imperial College LondonJosh D'AethElucidate shadow costs and enable policies to ensure mortality and costs are minimised across a healthcare system. Patient level data (CO-CIN) dataset.Internally fundedApproved26.05.202012.07.2020
70
Imperial College LondonJosh D'AethEstimating the Life Years Lost from COVID-19: A Microsimulation Modelling StudyIndividual data particularly age, sex, comorbidities, and outcomeInternally fundedApproved26.05.202012.07.2020
71
University of LondonCamilla BenfieldPCR based identification of SNPS within a host immunity gene and associations between alleles and haplotypes.PBMCs (cell pellets or DNA) from 250 sever COVID-19 patients and 250 mild cases (matched for age/gender). Patient data on ethnicity and co-morbidities also sought. Also combined nose and throat swab, or extracted DNA from these swabs. Funding pendingDuplication of planned work, will share data when available02.06.202012.07.2020
72
University of GlasgowMiguel PinedaInfluence of human glycosylation pathways in COVID-19 clinical outcomeRNA from infected tissues, throat swabs or nasal specimens, Samples from 2 patients groups: mild and severe disease outcomes (10-15 patients per group) Days 1,3,9 and 28. Associated clinical dataFunding for pilot study. Will apply for further funding with IDAMAC support.Approved02.06.202012.07.2020
73
Nottingham Trent UniversityGraham BallPrediction of host response to the disease benefit using systems biology approaches Omics data or biomarker panel data from patients and corresponsding clinical parameters, ethnicity and outcome data.Internally fundingDuplication of planned work, will share data when available29.05.202012.07.2020
74
COPD Consortium/ImperialPaul Cullinan Chloe Bloom Brian Lipworth Thomas Drake Annemarie Docherty Does inhaled corticosteroid use have an impact on clinical outcomes in patients with COVID-19 disease and either asthma or other chronic respiratory disease; and examindation of UK ISARIC data?All data from CRF v9.4, all admissions to date of data access; to include relevant measurements in plasma and other biosamples. Internal fundingApproved09.06.202012.07.2020
75
University of YorkNathalie Signoret Dimitris LagosPatients from Yorkshire and Humber - identify correlates of natural immunity, disease development, and recovery. Blood biomarkers of COVID-19 patients with a mixed demographic origin.Plasma (750ul - 1.5ml) from Tier 1 from adults. Up to 100 depending on availability.Start with repurposed funding, applying for UKRI rapid response rolling call.Duplication of planned work, will share data when available05.06.202012.07.2020
76
University of North CarolinaFei Zhou Baiming ZhouDeep learning models to predict COVID-19 outcomesAll outcome and clinical/baseline demographic variables at individual patient levelApplying for fundingDuplication of planned work, will share data when available05.06.202012.07.2020
77
University of CambridgeMahesh PrahladanRapid diagnosis of COVID-19 patients with AI algorithm using clinical and image analytical parameters to evaluate the lymphocyte subsets in peripheral blood.Clinical and laboratory parametersColchester and Ipswich Hospital Research Approved04.06.202012.07.2020
78
Medway NHS Foundation TrustAnnette WoodsDetermining whether medication taken by patients are protective or limits the prorgress of disease specific to Medway NHS TrustSite specific data from patients - demographics and all data submitted so far.Initial review do not need funding, further funding applications if succesful. Approved10.06.202012.07.2020
79
Non-academic teamRory DunneAid diagnosis and prognostic evaluation by using cytokine profiles to distinguish between concurrent outbreaks of influenza and coronavirusDemographics, outcomes, clinical data and cytokine dataSelf-funded, will apply for further funding if succesfulDenied 11.06.202012.07.2020
80
West Hertfordshire Hospitals NHS TrustRama VancheeswaranValidation cohort for risk prediction study with longer term outcomes called PREDICT COVID.Data from 5000 patients in population for external validation tool.Internally fundedApproved11.06.202012.07.2020
81
NCCID CollaborationMatthew Watt Combine ISARIC4C clinical data with chest images (X-ray, CT and MRI) that NCCID is collecting to support the response to COVID-19.Tier 0 data collected via CRF meeting selection criteria of NCCID databaseFunded by NHSx, would seek additionally funding if needed.Approved15.06.202012.07.2020
82
University of GlasgowColin Berry Alex McConnachie John Cleland Antonia Ho Characterise cardiac risk in COVID-19 to guide clinicians on risk stratification and therapy in high-risk groups.Database accessInternally fundedApproved16.06.202012.07.2020
83
Queen's University BelfastUltan PowerScreen FDA-approved drugs for antiviral and anti-inflammatory activities in vitro - using viral strains for validation.Access to 5 anonymised clinical samples (nasal/throat swabs or nasopharyngeal aspirates) from SARS-CoV-2 patients from different geographical locations. Access to 5 low passages (P4) SARS-CoV-2 strains.UKRI/NIHR COVID-19 Rapid ResponseApprove16.06.202012.07.2020
84
MC DiagnosticsPeter MaguireCommercial - HLA typing 1ug DNA per patient, capacity for over 1000 - application through GenoMICC.Internally fundedResubmission16.06.202012.07.2020
85
Epsom & St Helier University NHSRachel WakeInvestigating Trust specific nosocomial transmission to assist triaging and cohorting to prevent viral exposure to susceptible patients. Tier 0 data collected at Epsom & St HeliersInternally fundedApproved 16.06.202012.07.2020
86
University of OxfordLuis Sota MotaTest and compare the performance of different mortality prediction scores to support developing countriesClinical dataInternally fundedReferred to international team21.06.202012.07.2020
87
Phoenix Dx LtdAjanta ChakrabortyValidation of rapid POC diagnostic device Nasal and throat swabs (Priority 2,5,7 within 7-10 days of infection).Internally funded - commercialFurther questions22.06.202012.07.2020
88
Crick InstituteAndrew Bretherick, Markus Ralser, Kenneth BaillieInvestigate plasma proteome to inform clinical practice thourgh trajectories and associations, prognostic models of disease outcome and identify novel potential therapeutic targets40ul EDTA plasma - serial samples n=300. Tier 0 data - genetic data and demographic and clinical information.Francis Crick InstituteApproved22.06.202012.07.2020
89
Epsom & St Helier NHS TrustMedhi MirzazadehAlkaline Phosphatase levels as a prognostic biomarker of COVID-19 outcome in chronic kidney disease patientsOutcome data including lenght of hospital admission, ITU admission, oxygen requirement or death. Current known risk factors, including age, ethnicity, gender, diabetes, eGFR, BMI, pregnancy, Troponin, CRP, Ferritin, D-dimer levels and total serum Alkaline PhosphataseInternally fundedALP not recorded, denied25.06.202012.07.2020
90
Imperial College LondonAmna Malik Nichola CooperT-cell sequencing to identify differences between 'good responders (non-severe) and 'bad responders' (severe) patients to improve treatment outcomes.1ml of blood in blood RNA tube at day 1,3,9 and 28. Access to metadata - age, sex, disease status and other clinical information.Internally fundedFor discussion26.06.202012.07.2020
91
NHS Greater Glasgow & ClydeMichael Murphy15 x 1ml saliva samples from COVID-19 patients. Corresponding data if possible.CSO grantApproved26.06.202012.07.2020
92
University of LeedsJim RobinsonLocus specific genotyping of the Fc Gamma locusGenomic DNA or cell pellets. Minimum of 300ng DNA required. Associated ISARIC clinical dataMRC CICApproved01.07.202012.07.2020
93
Imperial College LondonRamya Sriskandarajah Sruthi RamarajuDynamic profile of immunological markers which independently predict COVID-19 outcomesData from the whole cohort for serum serial levels (day 1,3,9 and 28) for list of biomarkers. Clinical characteristics of patients, demographics, co-morbidities.Internally fundedDenied, for internal discussion02.07.202012.07.2020
94
London School of Hygiene and Tropical MedicineDaniel WardInnate and adaptive responses to SARS-CoV-2 infection - T- and B-cell receptor characterisation through deep seq of T/B-Cell receptor VDJ sequences. Multinational dataset - to include samples from Portugal, Brazil, Kenya, and Indonesia30ml x 20 patients of whole bood (with anticoagulant) at days 1,3,9 and 28. 500ul of sera from 100 patients with range of disease. MetadataInternally fundedDenied 06.07.202012.07.2020
95
University of EdinburghKenneth Baillie, Clark Russel, Natalie HomerQuantify steroid hormones including androgens and therapeutic dexamethasone in all cases440mcl plasmaISARIC 4C GrantApproved10.07.202012.07.2020
96
University of EdinburghKenneth Baillie, Clark Russel, Simon AbramsQuantify total Ig levels and subsets, and Albumin, in samples from all patients40mcl plasmaISARIC 4C GrantApproved10.07.202012.07.2020
97
University of Queensland - COVID-19 Critical Care ConsortiumJacky Suen John FraserLinking COVID-19 Critical Care Consortium database for UK sites with ISARIC databaseData from UK CCP database - characterise features of COVID-19 in ICU patientsUniversity of QueenslandApproved10.07.202012.07.2020
98
UK Coronavirus Immunology ConsortiumPaul MorganDetailed understanding of how the complement system responds to SARS-CoV-21000 plasma/EDTA samples, 1ml volume - range of immunoasssays. Matching genotype data. Clinical outcome and severity data.UKRI application pendingApproved08.07.202012.07.2020
99
University Hospitals North Midlands NHS TrustJenny WrightQuantitative PCR Ct values as predictors of poor outcomes for COVID-19 patients Data from local ISARIC4C datasetInternally fundedApproved13.07.202013.07.2020
100
Public Health ScotlandGeorgia LadburyData sharing with i-MOVE-COVID-19 Consortium to enhance surveillance and research to allow Scotland to contribute to an European-level COVID datasetFull CO-CIN dataset of patients hospitalised in Scotland Government fundedData is already being provided13.07.202013.07.2020